• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.6 no.1
• /
• pp.46-52
• /
• 2020

Radiopharmaceuticals that can be consumed in specific disease site play a key role In order to diagnose and treat the diseases. In addition, radiopharmaceuticals can be used for diagnostic or therapeutic purposes depending on the type of the labeled radioactive isotope. Recently, theragnostic radiopharmaceuticals that can simultaneously diagnose and treat are developed. Therefore, the development of target-specific radiopharmaceuticals is a very important research topic in the field of molecular imaging and therapy. This review paper summarizes the basic considerations for the development of radiopharmaceuticals. For new researchers or students who are now beginning in the field of radiopharmaceuticals, we intend to assist in the development of radiopharmaceuticals by describing the definition of radiopharmaceuticals, the ideal radiopharmaceutical conditions, the considerations for developing new radiopharmaceuticals, the factors affecting the design of radiopharmaceuticals, the requirements of radioisotope labeling reactions, and finally the definition and importance of molar activity in radiopharmaceuticals.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.1 no.2
• /
• pp.98-103
• /
• 2015

Good manufacturing Practice (GMP) regulation for diagnostic and therapeutic radiopharmaceuticals was prepared at 2014. The mandatory GMP regulation becomes effective on $1^{st}$, July 2015,with two years of grace periods. Korean radiopharmaceuticals GMP regulation was consisted of quality management, personnel, premise and facility, documentation, production, quality control and self-audit and they have a very similar structure to European Union and PIC/S GMP regulation. Here, we describe detailed description of GMP regulation each part and application to radiopharmaceuticals production. And we also compare Korea, Japan and USA radiopharmaceuticals GMP regulation. GMP is a method to maintain quality of radiopharmaceuticals in daily production and it must be embedded on the manufacturing operation and management.

• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.10a
• /
• pp.761-762
• /
• 2005

• Proceedings of the Korean Vacuum Society Conference
• /
• 2006.08a
• /
• pp.115-115
• /
• 2006

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.5 no.2
• /
• pp.120-128
• /
• 2019

Radiopharmaceuticals include therapeutic radiopharmaceuticals and diagnostic radiopharmaceuticals. Therapeutic radiopharmaceuticals are administered to the body and ingested at specific organs to detect radiation emitted from the site and to construct an image to diagnose the disease. Diagnostic radiopharmaceuticals are used to treat diseases by killing cells with radiation emitted from radiopharmaceuticals, such as cancer cells, vascular endothelial cells, arthritis, and Alzheimer's disease. The application possibilities of terahertz imaging technology for the combination of radiopharmaceuticals and molecular imaging medicine are discussed and experimental methods are presented. Terahertz imaging is expected to be a powerful technique because of the effective piercing feasibility, which enables to perform safe and high resolutive imaging. To investigate the response of cell to the terahertz wave, both the pulsed and CW THz wave systems are employed. THz imaging of a rat's paraffin-embedded epithelial cell with tumor is studied in advance.

• Bulletin of the Korean Chemical Society
• /
• v.26 no.11
• /
• pp.1865-1868
• /
• 2005

• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.05a
• /
• pp.948-949
• /
• 2005

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.8 no.2
• /
• pp.51-52
• /
• 2022

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.8 no.2
• /
• pp.157-166
• /
• 2022

Targeted alpha therapy began to be applied to the treatment of late-stage cancer patients because of its dramatic therapeutic efficacy in patients who have no responses with beta-emitting radiopharmaceuticals. However, its strong cytotoxicity may cause side effects due to undesirable uptake in non-target tissues. In order to use alpha-emitting radiopharmaceuticals for early-stage patients as well as late-stage cancer patients, therefore, modifications on their chemical structures are required. In this review, the recent progress in the development of alpha-emitting radiopharmaceuticals is discussed.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.3 no.2
• /
• pp.53-53
• /
• 2017